Comparative Pharmacology
Head-to-head clinical analysis: COMBOGESIC versus COMPOUND 65.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COMBOGESIC versus COMPOUND 65.
COMBOGESIC vs COMPOUND 65
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
COMBOGESIC (acetaminophen and tramadol) combines a centrally acting analgesic (tramadol) that binds to mu-opioid receptors and inhibits serotonin and norepinephrine reuptake, with an antipyretic (acetaminophen) that inhibits cyclooxygenase (COX) in the CNS.
COMPOUND 65 acts as a selective serotonin reuptake inhibitor (SSRI), increasing serotonin levels in the synaptic cleft by blocking the serotonin transporter (SERT).
One tablet (acetaminophen 500 mg / tramadol 37.5 mg) orally every 4 to 6 hours as needed for pain, not to exceed 8 tablets per day.
25 mg orally every 8 hours as needed for pain; maximum 75 mg per day.
None Documented
None Documented
Acetaminophen: 2-3 hours; Tramadol: 6.3 hours (slow CYP2D6 metabolizers may exceed 12 hours). Clinically, dosing interval adjusted for renal impairment.
Terminal elimination half-life is 8-12 hours in healthy adults; prolonged to 15-20 hours in hepatic impairment; requires dose adjustment in severe hepatic disease.
Renal excretion of acetaminophen metabolites (glucuronide, sulfate, cysteine, and mercapturate conjugates); 85% total. Tramadol and metabolites: 90% renal, 10% fecal.
Renal excretion of unchanged drug accounts for 30-40%; hepatic metabolism with fecal elimination of metabolites accounts for 50-60%; biliary excretion is minimal (<5%).
Category C
Category C
Analgesic Combination (Opioid + Non-Opioid)
Analgesic Combination (Opioid + NSAID)